论文部分内容阅读
Background Treatment of drug-eluting stent (DES) restenosis is still challenging with no established best strategy.The PEPCAD China ISR trial was to demonstrate the efficacy and safety of paclitaxelcoated balloon (PCB) Sequent Please (B Braun, Germany) compared to paclitaxel-eluting stent (PES) TAXUS Liberte (Boston Scientific, USA)in a Non-European patient population with DES restenosis.